Press "Enter" to skip to content

New patent for Allergan drug FETZIMA

2
Copyright © DrugPatentWatch. Originally published at New patent for Allergan drug FETZIMA

Annual Drug Patent Expirations for FETZIMA
Annual Drug Patent Expirations for FETZIMA

Fetzima is a drug marketed by Allergan and is included in one NDA. It is available from one supplier. There are three patents protecting this drug and one Paragraph IV challenge.

FETZIMA drug price trends.

Drug patent litigation for FETZIMA.

This drug has forty-eight patent family members in twenty-seven countries.

The generic ingredient in FETZIMA is levomilnacipran hydrochloride. One supplier is listed for this compound. Additional details are available on the levomilnacipran hydrochloride profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent for Allergan drug FETZIMA

Comments are closed.

Get the DrugPatentWatch Daily Briefing

✓ Patent Expirations and Generic Entry

✓ Insightful Articles & Case Studies

✓ Patent Litigation & Challenges

✓ 505(b)(2) & Biosimilars

✓ Industry Trends

Do NOT follow this link or you will be banned from the site!